Pretreatment of human mesenchymal stem cells with HMG-CoA reductase inhibitor improved efficiency of cardiomyogenic transdifferentiation

在这项研究中，我们的挑战是通过用HMG-CoA还原酶抑制剂预处理间充质干细胞（MSC）来提高体内间充质干细胞（MSC）移植的疗效。体外心肌诱导后，HMG-CoA还原酶抑制剂预处理显著提高心肌转分化效率（CTE），采用抗心肌肌钙蛋白- 1抗体进行免疫细胞化学计算。用HMG-CoA还原酶抑制剂和Akt抑制剂wortmannin预处理CTE。

In this study, our challenge was to improve the efficacy of mesenchymal stem cell (MSC)transplantation in vivo by pretreatment of MSCs with HMG-CoA reductase inhibitor. After cardiomyogenic induction in vitro, preteatment with HMG-CoA reductase inhibitor significantly increased the cardio- myogenic transdifferentiation ef ficiency (CTE), which was calculated by immunocytochemistry using anti-cardiac troponin- I antibody. CTE was reduced by pretreatment with HMG-CoA reductase inhibitor and wortmannin, inhibitor of Akt.